DDF Summit Berlin 2019 Presentations

Characterization of Subvisible Particles: Old Challenges and Newest Improvements


Anacelia Ríos Quiroz

Scientist - Group Leader Particle Lab Biologics

Roche

Root Cause Investigations for Visible Particles and Aggregation


Andreas Seidle

Head, Global Analytical Characterisation & Bioanalytics, Technical Development Biosimilars

Novartis

New EU Medical Device Regulation (MDR) - Notified Body Opinion


April Kent

Regulatory Affairs Manager, Devices

Amgen

MDR Impact on Pharma Companies


Bjorg Hunter

Regulatory Manager, Devices

GSK

Early Evaluation of Clinical Performance for Modified Release Products


Dr Carol Thomson

Chief Executive Officer

BDD Pharma

Crystallization Kinetics in ASDs


Christian Luebbert

Postdoc Pharmaceutical Formulations

TU Dortmund University

Drug Delivery Devices: Patient-Centered Technical and Business Opportunities - Biosimilars as Case-Study


Corinna Sonderegger

Head Portfolio Management, Device Development & Commercialization

Novartis

Importance of Establishing the Stability of Drug-Loaded Nanoparticles


Dr. Cornelus F. van Nostrum

Associate Professor

Utrecht University

Miniaturized Capacitive Devices for the Detection of Circulating Biomarkers, Enabling Real-Time Kinetic Measurements, Integrable with Microfluidic Systems


Federica Mantovani

Industrial Liaison

Elettra

Instability of Polysorbates in Protein Biopharmaceutics


Dr. Franziska Edelmann

Scientist - Pharma Technical Development Analytics

Roche

A Mesoporous Silica DDS - An Option for Liquisolid Drug Delivery Systems


Fred Monsuur

New Business Development and TCS Manager, Excipients

GRACE

Impact of ABC Transporters at the Blood Brain Barrier


Gert Fricker

Director, Institute of Pharmacy and Molecular Biotechnology

University of Heidelberg

Harnessing the Power of the Digital Exhaust and Digital ATM in Wellness Programs


Graham B Jones

Director of Innovation

Novartis

Challenges of IV in-use Stability for Biologics - Some Case Studies


Héloïse Audat

Head of Late Stage Formulation Development Unit, Biologics

Sanofi

Control Strategy Approaches in Continuous Manufacturing of Oral Solid Dosage Forms


Jacqueline Maximilien

Senior Scientist, Pharmaceutical Development

Janssen Research & Development

Benefits of Early Integration of Human Factors: A BYDURERON BCise Case Study


James Meehan

Associate Principal Scientist

AstraZeneca

Predicting the Future - Learning about Challenges with Injectable Formulations to Select the Right Primary Packaging


James K. Mellman

Device Manager

Novartis

Digital Design of Pharmaceutical Products and Processes - State of the Art and Challenges


Prof. Johannes Khinast

Director

Research Center Pharmaceutical Engineering

Smart Delivery of Actives by Polyrotaxanes Providing New Options for the Treatment of Niemann Pick Type C Disease (1)


Kerstin Egele & Gerhard Wenz

Doctoral Researcher | Professor

Saarland University

Challenges and Opportunities to Include Patient Centered Design in Industrial Drug Development


Leonie Wagner-Hattler

Formulation Scientist

F. Hoffmann-La Roche

How-to Use Oral Drug Delivery Technology Innovatively


Luigi Boltri

Director, Technology Development

Adare Pharmaceuticals

Re-Imagining your ODT Formulation


Mara van Haandel

Innovation Manager

DFE Pharma

Derisking the Fill and Finish Process of Biotech Products


Marie Wacquet

Drug Product Process Development Unit Manager, Biologics

Sanofi

New Surfactants in Wet Ball Milling and an Innovative Embedding of Nanocrystals into a Granulate Matrix


Dr. Matthias Rischer

Director Drug Delivery & Innovation Projects

Losan Pharma

End to End Solutions in Freeze Drying: From Cycle Audit through Formulation, Process Optimisation and Scale Up


Dr Mattia Cassanelli

International Technical Sales Executive

Biopharma Group

Formulation Impact on Patient Experience


Mike Hooven

CEO

Enable Injections

Optimization of Industrial Freeze Drying Cycle - Two Case Studies


Mostafa Nakach

Head of Pharmaceutical Engineering

Sanofi

Polyoxazoline: A Potent Alternative to PEG-Based Formulations of Hydrophobic Drugs


Prof Rainer Jordan

Chair of Macromolecular Chemistry, School of Science

TU Dresden

Hydroxylpropyl ß-Cyclodextrin: A Promising Excipient for Protein Stabilization


Rajeev Gokhale

Head Global Pharmaceutical Sciences R&D, Head Asia R&D

Roquette

Progressing the Development of AZD2811 Nanoparticles for Intravenous Administration


Dr Rebecca Booth

Senior Scientist

AstraZeneca

Human Factors Engineering for Medical Device Development


Rémy Vomscheid

Director, Device Development & Technologies

Ipsen

Risk Mitigation in Topical Product Development


Rob Turner

Vice President of Business Development and Innovation

MedPharm

GORE ImproJect Plunger: A New Option for Delivery of Sensitive Biologics in Pre-Filled Syringes


Russ Hornung

Business Development

W. L. Gore & Associates

Micro-Array Patches: Delivering High Drug Doses Transdermally


Prof Ryan F. Donnelly

Chair in Pharmaceutical Technology

Queen's University Belfast

Transmucosal Drug Delivery: Using the Mucofilm® Technology to Bypass the First Pass Effect


Dr. Sebastian Braun

Head of Science & Technology

tesa Labtec GmbH

Parental Sustained Release of Peptides and Proteins - Getting it Right


Simon Bjerregaard

Senior Research Scientist

Ferring

Rubber Components Selection for Optimal Drug Packaging


Simon Kervyn

Manager Material Development

Datwyler

How to use basic principles of Physics in pharmaceutical process development Application to granulation, coating and drying in Fluid Bed


Sophie Martin

Process Engineer in Pharmaceutical Development

Sanofi

Drug Delivery Recent Technology Trends and Solutions


Dr. Stefan Bracht

Head of Disruptive Technologies Chemical & Pharmaceutical Development

Bayer

Facilitating Meaningful Differentiation of Products by Establishing a Culture of Device Innovation to Support Rare Disease Treatment


Stefan Holzner

Senior Director and Head, Device Device Development

Takeda

Targeting Specific Patient Populations for Distinct Oral Dosing Formulation Challenges - Flexible Technology is Key


Prof Dr Sven Stegemann

Director, Pharmaceutical Business Development

Lonza Pharma & Biotech

Benefits and Challenges with Medical Software


Torsten Kneuss

QA Manager Combination Products

Bayer

Solid Dosage Forms for Heterogeneous Patient Groups: Challenges and Solutions


Veronique Henner-Kulkarni

Technical Sales Manager

ShinEtsu

Combination Products: Global Regulatory Landscape


Viky Verna

Co-Founder and VP

confinis

Dedicated to Better Health


Eleonor Cerasoli

Senior Research Scientist

Albumedix